Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
James L. Thorne, Melina C. Teske, Robyn V. Broad, Andrew M. Hanby, Laura M. Wastall, Stacey J. Jones, Thomas A. Hughes
Publikováno v:
British Journal of Cancer
Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027115557c95f3f47f1ecb119dec9f3d
Autor:
Koichi Kaneko, Heiji Yoshinaka, Takaaki Arigami, Sumiya Ishigami, Shinichi Ueno, Hiroshi Okumura, Shoji Natsugoe, Kazuhiro Tabata, Munetsugu Hirata, Yuko Kijima, Chihaya Koriyama, Akihiro Nakajo, Yoshiaki Shinden, Michiyo Higashi, Tadao Mizoguchi, Yoshikazu Uenosono, Hideo Arima, Kosei Maemura
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The aim of this study was to investigate the maintenance of volume as a spacer by comparing vascular supply and apoptosis in an implanted autologous-free dermal fat graft (FDFG) and free fat graft (FFG). An autologous FDFG is a material us
Publikováno v:
European Journal of Nutrition
Purpose Tamoxifen has been used for the treatment of estrogen receptor (ER)-positive breast cancers and in women who are at an increased risk of breast cancer. Acquired resistance to this drug and its toxicity still pose a clinically significant prob
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
Breast Cancer Research : BCR
Introduction Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib
Autor:
Engin Ozcivici, Melis Olcum
Publikováno v:
Cancer Cell International
Ozcivici, Engin/0000-0003-4464-0475
PubMed: 25349533
Introduction: Mechanical loads can regulate cell proliferation and differentiation at various stages of development and homeostasis. However, the extension of this regulatory effect of me
PubMed: 25349533
Introduction: Mechanical loads can regulate cell proliferation and differentiation at various stages of development and homeostasis. However, the extension of this regulatory effect of me
Autor:
Birgitte Bruun Rasmussen, Anne Katrine Duun-Henriksen, Sarah Larsen, Anne Vibeke Lænkholm, Christina Westmose Yde, Martin Bak, Anne E. Lykkesfeldt, Tove Kirkegaard
Publikováno v:
Larsen, S L, Yde, C W, Laenkholm, A-V, Rasmussen, B B, Duun-Henriksen, A K, Bak, M, Lykkesfeldt, A E & Kirkegaard, T 2015, ' Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer ', B M C Cancer, vol. 15, 239 . https://doi.org/10.1186/s12885-015-1210-4
BMC Cancer
BMC Cancer
BACKGROUND: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast canc
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Autor:
Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin
Publikováno v:
Breast Cancer Research : BCR
Introduction Neoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy r
Publikováno v:
BMC Cancer
Background Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that use of cyclooxygenase (COX) i
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)
BMC Cancer, 17(232). BMC
BMC Cancer
BMC Cancer, 17(232). BMC
BMC Cancer
Background Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia